Influx Healthtech IPO Subscription Status

Influx Healthtech IPO Subscription Status
Influx Healthtech IPO subscription started on 18 June, 2025 and will close on 20 June, 2025. The retail quota is 35%, QIB is 50% and NII is 15%. Influx Healthtech IPO got a lot of interest, raising around ₹61,00,800 shares (aggregating up to ₹58.57 Cr) Crores, with subscriptions 201.35 times overall, including 137.87 times by institutional investors, 481.1 times by non-institutional investors, and 117.68 times by retail investors. Shares are priced between ₹₹91 to ₹96 per share each and will be listed on the NSE.
  Check Live IPO  Subscription List  👈
Listed
Last Updated - June 20, 2025 5:55 pm

Influx Healthtech IPO Subscription - Day 3

QIB - Qualified Institutional Buyers: 137.87x
NII - Non-Institutional Investors: 481.1x
SNII - Small Non-Institutional Investors: [.]x
BNII - Big Non-Institutional Investors: [.]x
RII - Retail Individual Investor: 117.68x
Total: 201.35x 👈

Influx Healthtech IPO Investor Categories

  • Qualified Institutional Buyers: QIB
  • Non-Institutional Investors: NII
  • Small Non-Institutional Investors: SNII- Bid below ₹10L
  • Big Non-Institutional Investors: BNII- Bid above ₹10L
  • Retail Individual Investor: RII
  • Employees Quota: EMP

Influx Healthtech IPO Dates

IPO Activity Date
Open Date: 18 June, 2025
Close Date: 20 June, 2025
Allotment Date: 23 June, 2025
Refund Date: 24 June, 2025
Shares Credit Date: 24 June, 2025
Listing Date: 25 June, 2025

Influx Healthtech IPO Subscription Status FAQs

Q.When Influx Healthtech IPO Subscription will start?

Ans.The IPO subscription starts on 18 June, 2025 for Investors.


Q.What is the Influx Healthtech IPO Subscription last date?

Ans.Influx Healthtech IPO subscription last date is 20 June, 2025 for Investors.


Q.What is the Influx Healthtech IPO Allotment Date?

Ans.Influx Healthtech IPO allotment date is 23 June, 2025.


Q.What is the Influx Healthtech IPO Listing Date?

Ans.Influx Healthtech IPO listing date is 25 June, 2025. The IPO is to list on NSE.